CDKL5 and craniodiaphyseal dysplasia: Recent work utilizing a CDKL5-specific kinase inhibitor demonstrated reduced hippocampal LTP [57] which suggests unknown rodent specific compensations to genetic loss of Cdkl5. That said, downregulation of the mTOR signalling pathway has been reported across different mouse models of CDD [10, 55, 58].